Millennium Management
CGTX icon

Millennium Management’s Cognition Therapeutics CGTX Stock Holding History

Millennium Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,657
Closed -$87.3K – 5786
2025
Q4 		$87.3K Sell
64,657
-495,896
-88% -$805K ﹤0.01% 5651
2025
Q3 		$757K Buy
+560,553
New +$764K ﹤0.01% 4824
2024
Q3 		– Sell
-13,624
Closed -$22.6K – 6132
2024
Q2 		$22.6K Buy
+13,624
New +$27.2K ﹤0.01% 5522
2022
Q2 		– Sell
-14,536
Closed -$39K – 7016
2022
Q1 		$39K Sell
14,536
-41,883
-74% -$161K ﹤0.01% 6464
2021
Q4 		$357K Buy
+56,419
New +$550K ﹤0.01% 5357

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Millennium Management's CGTX Position: Q1 2026 in Review

Millennium Management sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 64,657 shares — an estimated $87.3K sold.

Millennium Management first reported a position in CGTX in Q4 2021 and held it in 5 quarters. The position peaked at $757K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Millennium Management reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 64,657 Cognition Therapeutics shares in Q1 2026, an estimated $87.3K.
  • Millennium Management first reported a position in Cognition Therapeutics in Q4 2021 and held it in 5 quarters.
  • Millennium Management's Cognition Therapeutics position peaked at $757K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.